secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001140361-25-041723
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US
-----------------------------------------------------------------------

- FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.
- Q3 2025: R&D expenses $16.8M, SG&A $5.8M; net operating cash outflow 9M $59.3M.
- Cash and cash equivalents $9.1M as of Sep 30, 2025.
- IPO net proceeds $80M used: $52.7M for DurAVR development, $18.3M for debt repayment and working capital.
- Related party payments in Q3: $515k (director fees, CEO, CFO remuneration).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125041723/0001140361-25-041723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125041723/ef20058755_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer